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Abstract
Anandamide (N-arachidonoylethanolamine, AEA) belongs to an emerging class of endogenous
lipids, called "endocannabinoids". A specific AEA membrane transporter (AMT) allows the import
of this lipid and its degradation by the intracellular enzyme AEA hydrolase. Here, we show that
synaptosomes from human, mouse and rat brain might be an ideal ex vivo system for the study of:
i) the accumulation of AEA in brain, and ii) the pharmacological properties of AMT inhibitors. Using
this ex vivo system, we demonstrate for the first time that glutamine and glutamate act as non-
competitive inhibitors of AEA uptake by human, mouse and rat brain AMT.
Findings
Endocannabinoids are an emerging class of lipid media-
tors, which activate cannabinoid receptors and regulate
sleep induction, interact with GABAergic, serotonergic
and dopaminergic neurotransmission, and are also
formed during glutamate-induced neurotoxicity [1,2].
The biological activity of anandamide (N-arachido-
noylethanolamine, AEA), a major endocannabinoid, is
controlled by cellular uptake through a specific AEA mem-
brane transporter (AMT) [3], followed by intracellular
degradation by anandamide hydrolase (fatty acid amide
hydrolase, FAAH) [4]. The critical role of AMT in control-
ling AEA action, and the potential use of AMT inhibitors
in the treatment of human pathologies such as multiple
sclerosis, Parkinson's disease and Huntington's disease
[1,5,6], prompted us to investigate whether brain synap-
tosomes might be used as a new ex vivo system, able to ac-
cumulate AEA through a selective transporter with the
features of AMT.
Human brain specimens were obtained from twelve dif-
ferent male patients (aged 73–77), undergoing surgical
operation to remove meningioma tumors from the pteri-
onal area. Brain tissues, removed and donated by Dr. G.
De Caro (Neurosurgery Division, University of Rome "Tor
Vergata", Sant'Eugenio Hospital, Rome, Italy), were kept
on ice until processed (within 30 min). In each case the
perilesional white matter (150 mg of fresh tissue) sur-
rounding the tumor area (300 mg) was removed and used
as healthy control [7]. Clearance of the local Ethnics Com-
mittee was obtained to use human brain biopsies. Swiss
mice weighing 20–25 g were from Charles River (Calco, It-
aly), and Wistar rats weighing 250–280 g were from
Morini (San Paolo D'Anza, Italy). All animal procedures
met the guidelines of the U.S. National Institutes of
Health, detailed in the Guide for the Care and Use of Labo-
ratory Animals, and the European Community directives
regulating animal research. The experimental procedures
were also approved by the local Animal Care Committee.
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To prepare synaptosomes from human, mouse or rat
brain, fresh tissues were resuspended in ice-cold 0.32 M
sucrose, 5 mM Tris.HCl buffer (pH 7.4) and were gently
disrupted by 10 up-and-down strokes in a Teflon-glass ho-
mogenizer (weight/volume ratio = 1:10). The homoge-
nate was centrifuged at 1000  g for 5 min, at 4C, the
supernatant was then centrifuged again at 17000  g for
15 min, at 4C. The final pellet was resuspended in 136
mM NaCl, 5 mM KCl, 0.16 mM CaCl2, 0.1 mM EGTA, 1.3
mM MgCl2, 10 mM glucose, 10 mM Tris.HCl buffer (pH
7.4), at a protein concentration of 1 mg/ml [8]. The activ-
ity of AMT and its kinetic properties were determined as
described [9]. Synaptosomes (100 l/test) were incubated
for different time intervals, at 37C or 4C to discriminate
carrier-mediated from non-carrier-mediated transport of
AEA through cell membranes, with 200 nM [3H]AEA (223
Ci/mmol; NEN Dupont de Nemours, Köln, Germany). Al-
ternatively, they were incubated for 15 min with different
concentrations of [3H]AEA, in the range 0–1000 nM (also
in this case, the uptake at 4C was subtracted from that at
37C). The kinetic constants of AMT, i.e. apparent Michae-
lis-Menten constant (Km) and maximum velocity (Vmax),
and the inhibition constant (Ki), were calculated by non-
linear regression analysis of the experimental points, us-
ing a Prism 3 program (GraphPAD Software for Science,
San Diego, CA). Q10 value was calculated as the ratio of
AEA uptake at 30C and 20C [9]. The effect of various
compounds (AEA, arachidonic acid, ethanolamine, D/L-
glutamine, D/L-glutamate, phenylmethylsulfonyl fluo-
ride (PMSF), iodoacetic acid, N-ethylmaleimide, sodium
nitroprusside (SNP), all from Sigma Chemical Co., St.
Louis, MO; 2-arachidonoylglycerol (2-AG) and N-(4-hy-
droxyphenyl)-arachidonoylamide (AM404), from Re-
search Biochemicals International, Natick, MA; VDM11,
from Tocris-Cookson, Bristol, UK; leukotriene B4 and
prostaglandin E2, from Cayman Chemical Company, Ann
Arbor, MI; 3-morpholinosydnonimine (SIN-1), from
Alexis Corporation, Läufelfingen, Switzerland) on AMT
activity was determined by adding directly each substance
to the assay buffer, at the indicated concentrations, and
incubating for 15 min at 37C [9]. Data are reported as
mean ( S.D.) of at least four independent determina-
tions, each performed in duplicate. Statistical analysis was
performed by the non-parametric Mann-Whitney test,
elaborating experimental data through the InStat 3 pro-
gram (GraphPAD Software for Science).
Synaptosomes prepared from human healthy brain (HB)
or human meningioma (HM) were found to take up
[3H]AEA with a saturable process, showing apparent Km
and Vmax values of 802  150 nM and 374  38 pmol/min
per mg protein, for HB, and 793  128 nM and 219  19
pmol/min per mg protein, for HM. Accumulation of 200
nM [3H]AEA was linear up to a synaptosome concentra-
tion of 500 g protein, and was undetectable in synapto-
somes pre-boiled for 5 min. It was also time- (t1/2 ~ 3 and
~5 min for HB and HM, respectively) and temperature-
(Q10 ~ 1.5 in both cases) dependent. Uptake of [3H]AEA
was dose-dependently inhibited by AM404 or VDM11, se-
lective AMT inhibitors [5,10]. Linear regression analysis
(r2 = 0.93) of the inhibition data yielded IC50 (concentra-
tion necessary to produce half-maximal inhibition) values
of ~7 M for both compounds in both tissues. This IC50
value is in the same range calculated in cell suspensions
[5,10]. The uptake of [3H]AEA was further characterized
in synaptosomes prepared from HM, which was available
in larger amounts than the healthy tissue. It was found
that accumulation of 200 nM [3H]AEA by HM synapto-
somes was fully inhibited by 1 M "cold" AEA, whereas
arachidonic acid and ethanolamine, the hydrolysis prod-
ucts generated from AEA by FAAH, were ineffective at con-
centrations up to 10 M. Moreover, the uptake of
[3H]AEA was not affected by leukotriene B4 or prostaglan-
din E2 (at 1 M), was inhibited (~50%) by alkylating
agents like PMSF, iodoacetic acid and N-ethylmaleimide
(each used at 100 M), and was enhanced (~180–220%)
by nitric oxide-donor SNP (at 5 mM) and peroxynitrite-
donor SIN-1 (at 1 mM), in much the same way as reported
for neuronal and non-neuronal cells in culture [3,7,9]. Re-
markably, 1 M 2-AG inhibited almost completely the up-
Table 1: Kinetic Constants of the AEA Membrane Transporter (AMT) in Brain Synaptosomes and Inhibition by Glutamine and 
Glutamate
Kinetic constant Human Meningioma Mouse Brain Rat Brain
Km (nM) 793  128 660  80 483  52
Vmax (pmol/min per mg protein) 219  19 370  23 357  18
Ki of L-Glutamine (nM)a 1100  90 970  80 850  80
Ki of D-Glutamine (nM)a 525  50 480  50 430  45
Ki of L-Glutamate (nM)a 4000  370 3580  300 3300  310
Ki of D-Glutamate (nM)a 1230  110 1100  90 850  80
aNon-competitive inhibitor of AMT in all cases.Lipids in Health and Disease 2002, 1 http://www.Lipidworld.com/content/1/1/1
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take of 200 nM [3H]AEA by AMT in meningioma
synaptosomes, again in line with previous observations
on cultured cells [3,9]. Taken together, these data suggest
that both healthy and tumoral brain accumulate [3H]AEA
by means of a selective transporter, most probably ex-
pressed in lower amounts in the tumoral than in the
healthy tissue. Also mouse brain (MB) and rat brain (RB)
synaptosomes were found to take up [3H]AEA with a sat-
urable process, showing apparent Km and Vmax values
comparable to those of AMT in human meningioma (Ta-
ble 1). Interestingly, for the first time glutamine and gluta-
mate were found to inhibit AMT in HM, MB and RB
synaptosomes in a dose-dependent manner, the L-enanti-
omers of both compounds being less effective than the
corresponding D-forms. Kinetic analysis of the inhibition
of AMT by D/L-glutamine or D/L-glutamate showed that
these compounds acted as non-competitive inhibitors of
AMT, with Ki values in the nM-M range and a potency D-
glutamine > L-glutamine > D-glutamate > L-glutamate
(Table 1). While it might be obvious that the amide was
more potent than the corresponding free acid in inhibit-
ing the amide transporter AMT, it remains unclear why the
D-enantiomers were more potent than the corresponding
L-forms. As yet, the lack of structural information on AMT
[3,5,9] does not allow a molecular interpretation of the
properties of this transporter. However, these unprece-
dented findings might be relevant for the role of AEA in
glutamate-induced neurotoxicity [1,2], because they sug-
gest a cross-talk between these two neurotransmitters. In-
deed, here it is shown that glutamate inhibits AEA
transport through AMT, whereas it has been already re-
ported that AEA inhibits synaptic release of glutamate [re-
viewed in ref. [11]]. This interplay between AEA and
glutamate might be relevant also in controlling excitotoxic
insults [12].
In summary, this study describes how to prepare synapto-
somes suitable to investigate presence and kinetic proper-
ties of the anandamide membrane transporter in human,
mouse and rat brain. This system allows to extend ex vivo
the model of AEA transport already described in vitro with
cell suspensions, and has the potential to provide insights
on the regulation and function of AMT in the context of
mature brain tissue, where control mechanisms lost in im-
mortalized cells might be retained. In this line, the finding
that AMT in synaptosomes is enhanced by nitric oxide-do-
nor SNP, and even more by peroxynitrite-donor SIN-1,
speaks in favour of a physiological meaning for the nitric
oxide-mediated link between AEA receptor and AEA deg-
radation, previously demonstrated in vitro[9]. Moreover,
the inhibition of AMT in human, mouse and rat brain syn-
aptosomes by glutamine and glutamate seems relevant to
better understand the role of AEA in glutamate-induced
neurotoxity. In conclusion, brain synaptosomes appear to
be a good tool for studies aimed at discovering new inhib-
itors of AMT of potential therapeutic value.
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